Cancer Protection, Metabolic, and Cardiovascular Health

How this polyphenol found in pomegranates, berries, and walnuts guards against cancer, supports metabolic health, and converts in the gut into powerful urolithin metabolites

Ellagic acid is a naturally occurring polyphenol found in pomegranates, raspberries, strawberries, blackberries, and walnuts. It has attracted serious scientific attention for its ability to slow cancer cell growth, regulate blood sugar and fat metabolism, and protect against chronic inflammation. Much of its benefit also comes from what it becomes after you eat it: gut bacteria convert ellagic acid into compounds called urolithins, which are absorbed into the bloodstream and carry their own distinct health effects [2].

Where Ellagic Acid Comes From

Ellagic acid does not exist freely in most foods — it arrives as part of larger molecules called ellagitannins, which are broken down during digestion and by gut bacteria to release ellagic acid. The richest sources are:

Pomegranate (peel and juice are especially concentrated)
Raspberries and blackberries
Strawberries
Walnuts
Muscadine grapes
Oak-aged red wine (in smaller amounts)

Because ellagitannins need to be hydrolyzed first, eating whole fruits and nuts provides a more sustained release than isolated supplements. Pomegranate juice concentrates ellagitannins from the peel and seeds, making it one of the most practical ways to increase intake.

The Urolithin Pathway

One of the most interesting aspects of ellagic acid is what happens to it in the gut. After absorption or bacterial processing, ellagic acid and its parent ellagitannins are metabolized by gut microbiota into a family of compounds called urolithins (urolithin A, B, C, and D) [2].

Urolithin A in particular has attracted intense research interest for its ability to activate mitophagy — the cellular process of clearing out damaged mitochondria — which is relevant to muscle aging, longevity, and metabolic health. See our urolithin A page for more on this downstream metabolite.

Whether you produce urolithins — and which type — depends on your gut microbiome composition. Individuals with richer, more diverse microbiomes tend to produce more urolithin A, which is associated with better cardiometabolic outcomes [5]. This means that improving gut health through diet and probiotics can amplify the benefits of eating ellagic acid-rich foods.

Anti-Inflammatory and Antioxidant Mechanisms

Ellagic acid works through several complementary pathways:

NF-κB inhibition: It suppresses the master switch of inflammation, reducing production of COX-2, iNOS, and pro-inflammatory cytokines [3].
Free radical scavenging: Ellagic acid neutralizes reactive oxygen species (ROS) directly, and also upregulates the body's own antioxidant enzymes.
Advanced glycation end product (AGE) inhibition: It interferes with the glycation process that damages proteins and is linked to diabetic complications and accelerated aging [3].

Metabolic Health Effects

Animal and cell studies show that ellagic acid helps regulate several metabolic processes [2]:

Lipid metabolism: Ellagic acid reduces triglyceride accumulation in fat cells and the liver, and helps regulate genes involved in fatty acid synthesis.
Blood sugar regulation: It reduces fasting glucose, improves insulin sensitivity, and inhibits glycation — the abnormal bonding of sugars to proteins that is central to diabetic complications.
Nonalcoholic fatty liver disease (NAFLD): In animal models, ellagic acid reduces liver fat accumulation and inflammation, offering a possible dietary adjunct for liver health.
Atherosclerosis: By reducing oxidized LDL and inflammatory signaling in blood vessel walls, ellagic acid may slow the progression of arterial plaque.

Dosage in animal studies typically ranges from 50–200 mg/kg body weight, which translates to doses higher than most people get from diet alone. Pomegranate supplementation is the most practical approach to meaningful intake.

Cardiovascular and Gut Connections

Research following people who ate pomegranates or walnuts found that those whose gut bacteria produced urolithin A — rather than urolithin B — had meaningfully better cardiometabolic markers: higher HDL-associated proteins and lower fasting glucose, especially in people with metabolic syndrome [5]. This links ellagic acid intake to cardiovascular risk reduction through the gut microbiome.

For those interested in related compounds, pomegranate also provides punicic acid and punicalagins; see our pomegranate page for the full picture.

Practical Guidance

To get meaningful ellagic acid from diet:

Eat a small handful of raspberries, blackberries, or strawberries daily
Include walnuts 4–5 times per week
Drink 200–240 mL (about 8 oz) of pure pomegranate juice several times a week, or eat half a pomegranate
Look for pomegranate extract supplements standardized to ellagitannin or ellagic acid content if targeting specific effects

Supporting a diverse gut microbiome — through fermented foods, fiber variety, and probiotic foods — increases your ability to convert ellagic acid into the beneficial urolithins that amplify its effects [5].

Evidence Review

Anti-Cancer Research

A 2023 review in Biomolecules by Čižmáriková et al. systematically examined how ellagic acid affects the recognized hallmarks of cancer [1]. The analysis found that ellagic acid influences at least seven cancer hallmarks:

It suppresses abnormal proliferative signaling and restores growth inhibitory responses.
It activates both the intrinsic (mitochondrial) and extrinsic (death receptor) apoptosis pathways in cancer cells while leaving healthy cells relatively unaffected.
It inhibits angiogenesis — the formation of new blood vessels that tumors require to grow beyond a few millimeters.
It reduces cancer cell migration and invasiveness, which are prerequisites for metastasis.
It restores immune surveillance mechanisms that cancer cells commonly evade.
It suppresses the chronic inflammatory tumor microenvironment that supports cancer progression.

A 2023 review in Cureus by Harper found that ellagic acid demonstrates anticarcinogenic activity across multiple cancer types including prostate, colon, and breast cancer in cell and animal models [4]. The author notes that ellagic acid may work synergistically with standard chemotherapy agents and identifies it as a low-risk dietary preventative measure, while acknowledging that large-scale human clinical trials are still limited.

Metabolic and Chronic Disease Research

The 2016 review by Kang et al. in Advances in Nutrition provides a detailed mechanistic account of how ellagic acid and its urolithin metabolites improve metabolic health [2]. In cell and animal models, ellagic acid:

Reduces expression of genes involved in de novo lipogenesis (fat synthesis)
Acts as an epigenetic regulator, modifying histone acetylation patterns that govern adipogenesis
Modulates gut microbiome composition, enriching bacteria associated with better metabolic outcomes

The authors emphasize that urolithin A — the primary gut metabolite — independently reproduces many of ellagic acid's anti-inflammatory and metabolic effects and may be more bioavailable in people with robust gut microbiomes.

The 2016 review by Derosa, Maffioli, and Sahebkar in Advances in Experimental Medicine and Biology focuses on ellagic acid in the context of cancer, diabetes, and chronic inflammation [3]. The authors note its inhibition of AGE formation as particularly relevant to diabetic complications and aging-related protein damage, a mechanism distinct from most other polyphenols.

Cardiometabolic Biomarker Study

The 2017 clinical study by Selma et al. in Clinical Nutrition followed individuals consuming pomegranate or walnut ellagitannins and measured which urolithin metabotype they produced [5]. Key findings:

Urolithin A producers showed significantly higher apolipoprotein A-I levels and intermediate-HDL cholesterol fractions.
In metabolic syndrome patients, urolithin A production correlated inversely with fasting glucose.
Urolithin B producers showed less favorable lipid profiles, including higher total and LDL cholesterol.
In patients on lipid-lowering drugs, urolithin A producers responded better to treatment.

The study had 230 participants and compared normoweight, overweight/obese, and metabolic syndrome groups, giving it reasonable ecological validity.

Evidence Limitations

The current body of evidence is primarily mechanistic (cell studies) and preclinical (animal models). Human randomized controlled trials on ellagic acid are limited in number and size. The variability in urolithin production between individuals — driven by microbiome differences — complicates predicting individual responses. However, the consistent direction of effects across multiple independent research groups, the low risk profile of ellagic acid-rich foods, and the mechanistic plausibility of its effects give the dietary evidence reasonable credibility for health-conscious food choices.

References

Ellagic Acid and Cancer Hallmarks: Insights from Experimental EvidenceČižmáriková M, Michalková R, Mirossay L, Mojžišová G, Zigová M, Bardelčíková A, Mojžiš J. Biomolecules, 2023. PubMed 38002335 →
Improvements in Metabolic Health with Consumption of Ellagic Acid and Subsequent Conversion into Urolithins: Evidence and MechanismsKang I, Buckner T, Shay NF, Gu L, Chung S. Advances in Nutrition, 2016. PubMed 27633111 →
Ellagic Acid and Its Role in Chronic DiseasesDerosa G, Maffioli P, Sahebkar A. Advances in Experimental Medicine and Biology, 2016. PubMed 27671829 →
A Review of the Dietary Intake, Bioavailability and Health Benefits of Ellagic Acid (EA) with a Primary Focus on Its Anti-Cancer PropertiesHarper P. Cureus, 2023. PubMed 37692691 →
The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkersSelma MV, González-Sarrías A, Salas-Salvadó J, Martín R, Chapple IL, Morales JC, Tomás-Barberán FA, Beltrán D. Clinical Nutrition, 2017. PubMed 28347564 →